Abstract
Introduction: In EGFR mutated advanced NSCLC, tyrosine kinase inhibitors are new valid options as first-line treatment. Gefitinib appears a valid alternative to chemotherapy as first-line therapy, in EGFR mutated elderly or unfit patients too, while erlotinib remains an option for subsequent lines of treatment. Areas covered: Areas covered in this review include two international trials, which evaluated erlotinib in chemo-naive EGFR mutated patients both in an Asian and caucasian population, showing a dramatic advantage in terms of progression-free survival and overall response rate as well as gefitinib. Results showed a good safety profile, with side effects of mild to moderate intensity, usually manageable with temporary interruption of treatment. Expert opinion: Investigating EGFR mutations is critical in order to obtain sufficient data. It has now become mandatory for molecular characterization, as part of baseline diagnostic procedures. This approach is also becoming increasingly important during progression of the disease as a sort of 'molecular follow up'. It plays a central role in the right choice of treatment, in an aim to give the best drug to the right patients, overcoming other well known prognostic factors.
| Original language | English |
|---|---|
| Journal | Expert Opinion on Therapeutic Targets |
| Volume | 16 |
| Issue number | SUPPL.2 |
| DOIs | |
| Publication status | Published - Apr 2012 |
Fingerprint
Keywords
- advanced NSCLC
- EGFR mutation
- erlotinib
- first-line treatment
- gefitinib
ASJC Scopus subject areas
- Drug Discovery
- Pharmacology
- Clinical Biochemistry
- Molecular Medicine
Cite this
Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer. / Gori, Bruno; Ricciardi, Serena; Del Signore, Ester; Fulvi, Alberto; De Marinis, Filippo.
In: Expert Opinion on Therapeutic Targets, Vol. 16, No. SUPPL.2, 04.2012.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer
AU - Gori, Bruno
AU - Ricciardi, Serena
AU - Del Signore, Ester
AU - Fulvi, Alberto
AU - De Marinis, Filippo
PY - 2012/4
Y1 - 2012/4
N2 - Introduction: In EGFR mutated advanced NSCLC, tyrosine kinase inhibitors are new valid options as first-line treatment. Gefitinib appears a valid alternative to chemotherapy as first-line therapy, in EGFR mutated elderly or unfit patients too, while erlotinib remains an option for subsequent lines of treatment. Areas covered: Areas covered in this review include two international trials, which evaluated erlotinib in chemo-naive EGFR mutated patients both in an Asian and caucasian population, showing a dramatic advantage in terms of progression-free survival and overall response rate as well as gefitinib. Results showed a good safety profile, with side effects of mild to moderate intensity, usually manageable with temporary interruption of treatment. Expert opinion: Investigating EGFR mutations is critical in order to obtain sufficient data. It has now become mandatory for molecular characterization, as part of baseline diagnostic procedures. This approach is also becoming increasingly important during progression of the disease as a sort of 'molecular follow up'. It plays a central role in the right choice of treatment, in an aim to give the best drug to the right patients, overcoming other well known prognostic factors.
AB - Introduction: In EGFR mutated advanced NSCLC, tyrosine kinase inhibitors are new valid options as first-line treatment. Gefitinib appears a valid alternative to chemotherapy as first-line therapy, in EGFR mutated elderly or unfit patients too, while erlotinib remains an option for subsequent lines of treatment. Areas covered: Areas covered in this review include two international trials, which evaluated erlotinib in chemo-naive EGFR mutated patients both in an Asian and caucasian population, showing a dramatic advantage in terms of progression-free survival and overall response rate as well as gefitinib. Results showed a good safety profile, with side effects of mild to moderate intensity, usually manageable with temporary interruption of treatment. Expert opinion: Investigating EGFR mutations is critical in order to obtain sufficient data. It has now become mandatory for molecular characterization, as part of baseline diagnostic procedures. This approach is also becoming increasingly important during progression of the disease as a sort of 'molecular follow up'. It plays a central role in the right choice of treatment, in an aim to give the best drug to the right patients, overcoming other well known prognostic factors.
KW - advanced NSCLC
KW - EGFR mutation
KW - erlotinib
KW - first-line treatment
KW - gefitinib
UR - http://www.scopus.com/inward/record.url?scp=84858958689&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84858958689&partnerID=8YFLogxK
U2 - 10.1517/14728222.2011.652617
DO - 10.1517/14728222.2011.652617
M3 - Article
C2 - 22443258
AN - SCOPUS:84858958689
VL - 16
JO - Expert Opinion on Therapeutic Targets
JF - Expert Opinion on Therapeutic Targets
SN - 1472-8222
IS - SUPPL.2
ER -